Icon (NASDAQ:ICLR) was upgraded by analysts at Credit Suisse Group to a “buy” rating in a research note issued on Friday. The firm presently has a $131.00 price objective on the medical research company’s stock. Credit Suisse Group’s target price points to a potential upside of 13.90% from the company’s current price.
Several other research firms have also recently weighed in on ICLR. Zacks Investment Research cut Icon from a “buy” rating to a “hold” rating and set a $128.00 price target for the company. in a research note on Wednesday, January 3rd. SunTrust Banks restated a “buy” rating and issued a $133.00 price target on shares of Icon in a research note on Monday, January 22nd. KeyCorp restated an “overweight” rating and issued a $125.00 price target (up previously from $115.00) on shares of Icon in a research note on Monday, November 13th. They noted that the move was a valuation call. ValuEngine upgraded Icon from a “hold” rating to a “buy” rating in a research note on Sunday, December 31st. Finally, Evercore ISI began coverage on Icon in a research note on Thursday, January 18th. They issued an “outperform” rating and a $126.00 price target for the company. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Icon presently has an average rating of “Buy” and a consensus price target of $126.00.
Icon (NASDAQ ICLR) opened at $115.01 on Friday. The stock has a market capitalization of $6,165.75, a price-to-earnings ratio of 22.42, a price-to-earnings-growth ratio of 1.60 and a beta of 0.48. Icon has a one year low of $76.46 and a one year high of $124.48. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.90 and a current ratio of 1.90.
Institutional investors have recently bought and sold shares of the stock. Financial Gravity Companies Inc. purchased a new stake in Icon during the fourth quarter valued at $144,000. SG Americas Securities LLC purchased a new stake in Icon during the third quarter valued at $148,000. C M Bidwell & Associates Ltd. purchased a new stake in Icon during the fourth quarter valued at $196,000. Advisor Partners LLC purchased a new stake in Icon during the fourth quarter valued at $201,000. Finally, Dean Capital Investments Management LLC purchased a new stake in Icon during the fourth quarter valued at $203,000. Institutional investors own 89.66% of the company’s stock.
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.